Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Early Intra-aortic Balloon Pump Use After Venoarterial Extracorporeal Membrane Oxygenation

NCT06872021 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2026-03-22
Last updated
2026-03-24

Condition(s) studied

ECMO

Investigational drug(s) / intervention(s)

Early IABP useConventional approach

Early IABP use: Patients receive IABP for left ventricular unloading within 6 hours after VA-ECMO initiation.

Conventional approach: Patients do not receive mechanical unloading within 6 hours after VA-ECMO initiation.

Study summary

The goal of this multicenter, randomized trial is to compare early early left ventricular unloading by Intra-aortic Balloon Pump (IABP) versus conventional approach in patients with cardiogenic shock (CS) undergoing venoarterial extracorporeal membrane oxygenation (VA-ECMO). The main question it aims to answer is :

• If left ventricular unloading by IABP as compared with the conventional approach will improve the outcomes in patients undergoing VA-ECMO.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age of ≥18 2. Cardiogenic shock(defined as a systolic blood pressure of less than 90 mm Hg for more than 30 minutes or the initiation of catecholamines to maintain a systolic pressure of more than 90 mm Hg, an arterial lactate level of more than 3 mmol per liter, and signs of impaired organ perfusion) 3. Successful implantation of VA-ECMO 4. Informed consent Exclusion Criteria: 1. SCAI shock stage A or B 2. Presence of moderate to severe aortic insufficiency or aortic dissection 3. Severe peripheral vascular disease 4. Post-cardiotomy cardiogenic shock(non-CABG procedure) or bridging to cardiac procedure(heart transplantation or LVAD). 5. VA-ECMO for definite non-cardiac causes 6. Isolated right ventricular failure 7. V-A ECMO usage confined to the period during surgery or other interventions 8. Ischemic mechanical complications(eg Ventricular septal defect, papillary muscle rupture) 9. Extracorporeal cardiopulmonary resuscitation 10. LVAD, Impella or IABP in situ. 11. Severe bleeding 12. Terminal malignancy 13. Irreversible neurologic injury 14. Pregnancy or lactation

Primary outcome measure(s)

  • 30-day mortality — 30 days

Trial sites (1)

FacilityCityRegionStatus
Beijing Anzhen Hospital Beijing Beijing Municipality Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06872021 on ClinicalTrials.gov ↗ ← All trials in China